Johanna M. Niers

Johanna M. Niers

Auto-generated profile, based on publicly available information

Johanna M. Niers

Amsterdam UMC location Vrije Universiteit Amsterdam, Neurology , Amsterdam

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2023 in Cancer Research
Verified
Journal Article
Open access
PDF file
TMTathiane M. Malta
Tathiane M. Malta
TSThais S. Sabedot
Thais S. Sabedot
NMNatalia S. Morosini
Natalia S. Morosini
IDIndrani Datta
Indrani Datta
LGLuciano Garofano
Luciano Garofano
HNHoutan Noushmehr
Houtan Noushmehr
Tumor adaptation or selection is thought to underlie therapy resistance in glioma. To investigate longitudinal epigenetic evolution of gliomas in response to therapeutic pressure, we performed an epigenomic analysis of 132 matched initial and recurrent tumors from patients with IDH-wildtype (IDHwt) and IDH-mutant (IDHmut) glioma. IDHwt gliomas showed a stable epigenome over time with relatively low levels of global methylation. The epigenome of IDHmut gliomas showed initial high levels of genome-wide DNA methylation that was progressively reduced to levels similar to those of IDHwt tumors. Integration of epigenomics, gene expression, and functional genomics identified HOXD13 as a master regulator of IDHmut astrocytoma evolution. Furthermore, relapse of IDHmut tumors was accompanied by histologic progression that was associated with survival, as validated in an independent cohort. Finally, the initial cell composition of the tumor microenvironment varied between IDHwt and IDHmut tumors and changed differentially following treatment, suggesting increased neoangiogenesis and T-cell infiltration upon treatment of IDHmut gliomas. This study provides one of the largest cohorts of paired longitudinal glioma samples with epigenomic, transcriptomic, and genomic profiling and suggests that treatment of IDHmut glioma is associated with epigenomic evolution toward an IDHwt-like phenotype. Significance: Standard treatments are related to loss of DNA methylation in IDHmut glioma, resulting in epigenetic activation of genes associated with tumor progression and alterations in the microenvironment that resemble treatment-naïve IDHwt glioma.

1 January 2023 in Neuro-Oncology Advances
Verified
Journal Article
Open access
PDF file
KGKarin A van Garderen
Karin A van Garderen
WVWies R Vallentgoed
Wies R Vallentgoed
ALAnna Lavrova
Anna Lavrova
JNJohanna M Niers
Johanna M Niers
WLWendy W J de Leng
Wendy W J de Leng
MSMarion Smits
Marion Smits
Background: The T2-FLAIR mismatch sign is defined by signal loss of the T2-weighted hyperintense area with Fluid-Attenuated Inversion Recovery (FLAIR) on magnetic resonance imaging, causing a hypointense region on FLAIR. It is a highly specific diagnostic marker for IDH-mutant astrocytoma and is postulated to be caused by intercellular microcystic change in the tumor tissue. However, not all IDH-mutant astrocytomas show this mismatch sign and some show the phenomenon in only part of the lesion. The aim of the study is to determine whether the T2-FLAIR mismatch phenomenon has any prognostic value beyond initial noninvasive molecular diagnosis. Methods: Patients initially diagnosed with histologically lower-grade (2 or 3) IDH-mutant astrocytoma and with at least 2 surgical resections were included in the GLASS-NL cohort. T2-FLAIR mismatch was determined, and the growth pattern of the recurrent tumor immediately before the second resection was annotated as invasive or expansive. The relation between the T2-FLAIR mismatch sign and tumor grade, microcystic change, overall survival (OS), and other clinical parameters was investigated both at first and second resection. Results: The T2-FLAIR mismatch sign was significantly related to Grade 2 (80% vs 51%), longer post-resection median OS (8.3 vs 5.2 years), expansive growth, and lower age at second resection. At first resection, no relation was found between the mismatch sign and OS. Microcystic change was associated with areas of T2-FLAIR mismatch. Conclusions: T2-FLAIR mismatch in IDH-mutant astrocytomas is correlated with microcystic change in the tumor tissue, favorable prognosis, and Grade 2 tumors at the time of second resection.

31 July 2025 in Neuro-Oncology Practice
Verified
Journal Article
Open access
PDF file
MBMarieke E C Blom
Marieke E C Blom
MGMaxine Gorter
Maxine Gorter
VBVera Belgers
Vera Belgers
JRJantine G Röttgering
Jantine G Röttgering
PHPhilip C de Witt Hamer
Philip C de Witt Hamer
LDLinda Douw
Linda Douw
Background: Knowledge about glioma patients’ physical functioning and physical fitness throughout the disease trajectory is limited. We analyzed self-reported functioning and fitness in a large sample of glioma patients preoperatively and after primary treatment. Methods: We used the physical functioning subscale of the 36-Item Short Form Health Survey (SF36) and three questions about physical fitness from the Checklist of Individual Strength (CIS20). Scores were compared to age-, sex-, and education-matched population controls, preoperatively and after treatment. In patients with repeated assessments, changes over time were analyzed. Correlations between patient, disease, and treatment characteristics and functioning and fitness at both time points, and with change over time, were explored. Analyses were performed separately for World Health Organization grade II, III, and IV glioma. Results: Grade III patients had significantly lower functioning than controls, both preoperatively and after treatment, and declined over time. No significant differences with controls were found for grade II and IV patients, or for fitness. Grade II patients reported better functioning than grade III and IV preoperatively and better than grade III after treatment. Lower Karnofsky Performance Status was generally related to lower functioning and fitness, while older age, female sex, and lower education appeared in subgroup analyses. Age, neurological disabilities and tumor histology were associated with changes over time. Conclusions: Grade III glioma patients showed poorer functioning than population controls, which declined over time. Grade II patients reported better outcomes than the other subgroups, although individual variability was high. These findings highlight the need for personalized approaches addressing functioning and fitness in glioma.

4 March 2024
Verified
Other
Open access
TMTathiane M. Malta
Tathiane M. Malta
TSThais S. Sabedot
Thais S. Sabedot
NMNatalia S. Morosini
Natalia S. Morosini
IDIndrani Datta
Indrani Datta
LGLuciano Garofano
Luciano Garofano
WYW. K. Alfred Yung
W. K. Alfred Yung
Table S6: Deconvolution cell proportions and probe-signature matrix S6A: Methylcibersort cell proportions S6B: Methylcibersort cell reference mixture

4 March 2024
Verified
Other
Open access
TMTathiane M. Malta
Tathiane M. Malta
TSThais S. Sabedot
Thais S. Sabedot
NMNatalia S. Morosini
Natalia S. Morosini
IDIndrani Datta
Indrani Datta
LGLuciano Garofano
Luciano Garofano
WYW. K. Alfred Yung
W. K. Alfred Yung
Table S2: List of 132 pairs (ID of Initial and Recurrent samples)

4 March 2024
Verified
Other
Open access
TMTathiane M. Malta
Tathiane M. Malta
TSThais S. Sabedot
Thais S. Sabedot
NMNatalia S. Morosini
Natalia S. Morosini
IDIndrani Datta
Indrani Datta
LGLuciano Garofano
Luciano Garofano
WYW. K. Alfred Yung
W. K. Alfred Yung
Table S6: Deconvolution cell proportions and probe-signature matrix S6A: Methylcibersort cell proportions S6B: Methylcibersort cell reference mixture